HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Annovis Bio (NYSE:ANVS) and maintained a price target of $23.
June 12, 2024 | 10:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Annovis Bio and maintained a price target of $23, indicating continued confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $23 price target by a reputable analyst firm like HC Wainwright & Co. suggests strong confidence in Annovis Bio's future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100